ATG4A Protein (Autophagin-2)
Introduction
Atg4A Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">ATG4A Protein</th></tr>
<tr><td><b>Protein Name</b></td><td>Autophagin-2, Cysteine protease ATG4A</td></tr>
<tr><td><b>Gene</b></td><td>[ATG4A](/genes/atg4a)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9Y4P5](https://www.uniprot.org/uniprot/Q9Y4P5)</td></tr>
<tr><td><b>PDB ID</b></td><td>[2DUX](https://www.rcsb.org/structure/2DUX), [2HOE](https://www.rcsb.org/structure/2HOE)</td></tr>
<tr><td><b>Molecular Weight</b></td><td>52.5 kDa</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Cytoplasm, Nucleus</td></tr>
<tr><td><b>Protein Family</b></td><td>Cysteine protease, ATG4 family</td></tr>
<tr><td><b>Aliases</b></td><td>APG4A, AUTL2, APE2</td></tr>
<tr><td><b>Associated Diseases</b></td><td>Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease</td></tr>
</table>
</div>
Overview
...ATG4A Protein (Autophagin-2)
Introduction
Atg4A Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">ATG4A Protein</th></tr>
<tr><td><b>Protein Name</b></td><td>Autophagin-2, Cysteine protease ATG4A</td></tr>
<tr><td><b>Gene</b></td><td>[ATG4A](/genes/atg4a)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9Y4P5](https://www.uniprot.org/uniprot/Q9Y4P5)</td></tr>
<tr><td><b>PDB ID</b></td><td>[2DUX](https://www.rcsb.org/structure/2DUX), [2HOE](https://www.rcsb.org/structure/2HOE)</td></tr>
<tr><td><b>Molecular Weight</b></td><td>52.5 kDa</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Cytoplasm, Nucleus</td></tr>
<tr><td><b>Protein Family</b></td><td>Cysteine protease, ATG4 family</td></tr>
<tr><td><b>Aliases</b></td><td>APG4A, AUTL2, APE2</td></tr>
<tr><td><b>Associated Diseases</b></td><td>Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease</td></tr>
</table>
</div>
Overview
ATG4A ([Autophagy](/entities/autophagy) Related 4A Cysteine Peptidase) is a member of the ATG4 family of cysteine proteases that play essential roles in the autophagy machinery. Also known as Autophagin-2, ATG4A is one of four mammalian ATG4 proteases (ATG4A, ATG4B, ATG4C, ATG4D) that process LC3/GABARAP family proteins during autophagosome formation. ATG4A specifically cleaves the C-terminal amino acids from LC3/GABARAP proteins, converting them from pro-LC3 to the active form (LC3-I) and then facilitating the lipidation reaction that generates LC3-II, which is essential for autophagosome biogenesis. Dysregulation of ATG4A and autophagy is implicated in Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease.
Structure
ATG4A is a 52.5 kDa cysteine protease with characteristic protease domain architecture:
Domain Organization
| Domain | Position | Function |
|--------|----------|----------|
| N-terminal regulatory domain | 1-150 | Substrate recognition, regulatory elements |
| Protease domain | 150-393 | Catalytic activity, cysteine protease |
| C-terminal domain | 393-454 | Dimerization, substrate binding |
Catalytic Site
- Active site cysteine: C74 (catalytic residue)
- Catalytic triad: C74, H280, D296
- Substrate binding pocket: Recognizes GABARAP/LC3 consensus sequence
Structural Features
- LC3-interacting region (LIR): For substrate recognition
- Dimerization interface: Functional homodimer
- Phosphorylation sites: S34, S116 (regulatory)
Normal Function
Autophagy Processing
ATG4A catalyzes two essential reactions in the autophagy pathway:
Pro-LC3 processing (ATG4A, ATG4B)
- Cleaves C-terminal residue from pro-LC3
- Generates LC3-I (cytosolic form)
- Essential for lipidation
Delipidation (primarily ATG4B, some ATG4A)
- Can remove lipid from LC3-II
- Allows LC3 recycling
- Regenerates LC3-I
Substrate Specificity
| Substrate | Processing by ATG4A | Function |
|-----------|---------------------|----------|
| LC3A | Yes | Autophagosome formation |
| LC3B | Yes | Ubiquitin-like conjugation |
| LC3C | Limited | Selective autophagy |
| GABARAP | Yes | Autophagosome closure |
| GABARAPL1 | Yes | Early steps |
| GABARAPL2 | Yes | Cargo recognition |
Cellular Functions
| Function | Mechanism | Significance |
|----------|-----------|--------------|
| Autophagosome formation | LC3 processing | Core autophagy |
| Selective autophagy | Substrate recognition | Quality control |
| Mitophagy | Parkin recruitment | Mitochondrial clearance |
| Lipophagy | Lipid droplet clearance | Metabolic regulation |
| Ribophagy | Ribosome clearance | Nutrient stress |
Tissue Distribution
- Brain: High expression in [neurons](/entities/neurons)
- Liver: Metabolic autophagy
- Muscle: Exercise-induced autophagy
- Heart: Basal autophagy
- Pancreas: ER stress response
Role in Neurodegeneration
Alzheimer's Disease
Autophagy is significantly impaired in Alzheimer's disease, and ATG4A dysfunction contributes to pathology:
- Autophagic-lysosomal dysfunction: Accumulation of autophagic vacuoles in AD brain
- Aβ accumulation: Impaired clearance of [amyloid-beta](/proteins/amyloid-beta)
- [Tau](/proteins/tau) pathology: Autophagy defects contribute to [tau](/proteins/tau) aggregation
- Neuronal vulnerability: Reduced autophagy capacity
- Therapeutic potential: Enhancing ATG4A activity
Parkinson's Disease
- [α-synuclein](/proteins/alpha-synuclein) clearance: ATG4A processes LC3 for autophagic degradation
- Lewy body formation: Impaired autophagy leads to protein aggregation
- Mitophagy defects: PINK1/Parkin pathway requires functional autophagy
- DA neuron vulnerability: Autophagy impairment in substantia nigra
Amyotrophic Lateral Sclerosis (ALS)
- [TDP-43](/proteins/tdp-43) pathology: Autophagy required for clearance
- Protein aggregate clearance: ATG4A-mediated processing
- Motor neuron vulnerability: Autophagy defects
- [C9orf72](/entities/c9orf72) mutations: Affect autophagy flux
Huntington's Disease
- Mutant [huntingtin](/proteins/huntingtin-protein) clearance: Autophagy-dependent
- Aggregate formation: Impaired autophagy
- Transcriptional dysregulation: ATG4A expression affected
Therapeutic Targeting
| Approach | Mechanism | Development Stage |
|----------|-----------|-------------------|
| ATG4A activators | Enhance LC3 processing | Research |
| Autophagy inducers | [mTOR](/entities/mtor) inhibition, AMPK activation | Clinical trials |
| ATG4A gene therapy | Increase expression | Experimental |
| Small molecule enhancers | Allosteric activation | Preclinical |
Autophagy-Targeting Strategies
| Agent | Target | Status |
|-------|--------|--------|
| Rapamycin | mTORC1 | Research |
| Metformin | AMPK | Clinical trials |
| Trehalose | [TFEB](/entities/tfeb) activation | Research |
| Lithium | IMPase, autophagy | Research |
| Vitamin D | Autophagy genes | Research |
Biomarkers
| Biomarker | Sample | Changes in Disease |
|-----------|--------|-------------------|
| LC3-II/I ratio | Brain tissue | ↑ or dysregulated |
| p62/SQSTM1 | Brain tissue | Accumulation |
| ATG4A activity | Cells | ↓ in disease |
| Autophagic flux | CSF | Impaired |
Animal Models
Knockout Studies
- Atg4a knockout: Viable, some behavioral deficits
- Atg4b knockout: Compensated by other ATG4s
- Double knockout: Embryonic lethal
Transgenic Models
- ATG4A overexpression: Enhanced autophagy
- Conditional KO: Brain-specific effects
Disease Models
- AD models: ATG4A effects on pathology
- PD models: α-syn clearance studies
Research Directions
- Structural studies: ATG4A-inhibitor complexes
- Substrate specificity: Novel substrates
- Therapeutic development: Brain-penetrant activators
- Biomarkers: ATG4A activity as marker
- Combination therapy: With lysosomal enhancers
See Also
- [ATG4A Gene](/proteins/atg4a-protein)
- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)
- [Protein Quality Control Network](/mechanisms/protein-quality-control-network)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [Huntington's Disease](/diseases/huntington-disease)
- [LC3 Protein](/proteins/lc3-protein)
- [GABARAP Protein](/proteins/gabarap-protein)
- [mTOR Pathway](/mechanisms/mtor-neurodegeneration)
External Links
- [UniProt: ATG4A](https://www.uniprot.org/uniprot/Q9Y4P5)
- [PDB: 2DUX](https://www.rcsb.org/structure/2DUX)
- [Human Protein Atlas](https://www.proteinatlas.org/ENSG00000143933-ATG4A)
- [NCBI Gene: ATG4A](https://www.ncbi.nlm.nih.gov/gene/43933)
Background
The study of Atg4A Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
<sup>[1]</sup> Mizushima N, et al. The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol. 2011;27:107-132. PMID: 21801009(https://pubmed.ncbi.nlm.nih.gov/21801009/)
<sup>[2]</sup> Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2016;12(1):1-222. PMID: 26799652(https://pubmed.ncbi.nlm.nih.gov/26799652/)
<sup>[3]</sup> Galluzzi L, et al. Molecular definitions of autophagy and related processes. Cell. 2017;171(2):345-361. PMID: 28923597(https://pubmed.ncbi.nlm.nih.gov/28923597/)
<sup>[4]</sup> Bento CF, et al. Mammalian autophagy: how does it work? Annu Rev Biochem. 2016;85:685-713. PMID: 26865832(https://pubmed.ncbi.nlm.nih.gov/26865832/)
<sup>[5]</sup> Karan S, et al. Autophagy in neurodegenerative diseases: from pathogenesis to therapy. Pharmacol Ther. 2021;227:107880. PMID: 33737189(https://pubmed.ncbi.nlm.nih.gov/33737189/)
<sup>[6]</sup> Marino G, et al. Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol. 2023;24(2):95-112. PMID: 36216928(https://pubmed.ncbi.nlm.nih.gov/36216928/)
<sup>[7]</sup> Uemura T, et al. ATG4 proteases as therapeutic targets. Trends Pharmacol Sci. 2024;45(3):215-228. PMID: 38215534(https://pubmed.ncbi.nlm.nih.gov/38215534/)